Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

L'étude nationale finlandaise visant à faciliter l'accès des patients à des médicaments anticancéreux ciblés (FINPROVE)

9 novembre 2026 mis à jour par: Katriina Jalkanen, Helsinki University Central Hospital

L'étude nationale finlandaise visant à faciliter l'accès des patients à des médicaments anticancéreux ciblés afin de déterminer l'efficacité du traitement des cancers avancés avec un profil moléculaire connu

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Aperçu de l'étude

Description détaillée

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

Type d'étude

Interventionnel

Inscription (Estimé)

250

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Kuopio, Finlande
        • Recrutement
        • Kuopio University Hospital
        • Contact:
          • Okko Kääriäinen, MD
      • Oulu, Finlande
        • Recrutement
        • Oulu University Hospital OYS Cancer Center
        • Contact:
          • Sanna Iivanainen, MD. PhD.
      • Tampere, Finlande
        • Recrutement
        • Tampere University Hospital Department of Oncology
        • Contact:
          • Minna Tanner, MD, PhD
    • Southwest Finland
      • Turku, Southwest Finland, Finlande
        • Recrutement
        • Turku University Hospital Cancer Centre
        • Contact:
          • Erika Alanne, MD, PhD
    • Uusimaa
      • Helsinki, Uusimaa, Finlande, 00029
        • Recrutement
        • Helsinki University Hospital Comprehensive Cancer Center
        • Contact:
          • Tanja Juslin
        • Chercheur principal:
          • Katriina Jalkanen, MD, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 100 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

  2. ECOG performance status 0-2

  3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

    1. Absolute neutrophil count ≥ 1.5 x 109/l
    2. Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
    3. Platelets > 75 x 109/l (not applicable for hematological patients)
    4. Total bilirubin < 1.5 x ULN
    5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
  4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

  5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

  6. Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

  7. A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

  8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

  9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

  1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

  2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

    1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
    2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
  3. Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention

  4. Patient is pregnant or nursing.

  5. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.

  6. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  7. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  8. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

  9. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

  10. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Alectinib

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

ALK

Autres noms:
  • Alecensa
Expérimental: Cobimetinib

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

MEK1, MEK2

Autres noms:
  • Cotellic
Expérimental: Vismodegib

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

Hedgehog

Autres noms:
  • Erivedge
Expérimental: Trastuzumab+Pertuzumab

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

HER2

Autres noms:
  • Phesgo
Expérimental: Entrectinib

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

NTRK/ ROS1, ALK

Autres noms:
  • Rozlytrek
Expérimental: Atezolizumab

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

PD-L1

Autres noms:
  • Tecentriq
Expérimental: Vemurafenib

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

BRAF V600

Autres noms:
  • Zelboraf
Expérimental: Regorafenib

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

KIT/BRAF, RET

Autres noms:
  • Stivarga
Expérimental: Apalutamide

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

AR

Autres noms:
  • Erléada
Expérimental: Abemaciclib

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

CDK4/6

Autres noms:
  • Verzenio
Expérimental: Tepotinib

For patients with a molecular tumor profile that can potentially be targeted by tepotinib.

MET ex14

Autres noms:
  • Tepmetko
Expérimental: Dabrafenib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

RAF

Autres noms:
  • Tafinlar
Expérimental: Trametinib

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

MEK1, MEK2

Autres noms:
  • Mekiniste
Expérimental: Dabrafenib+Trametinib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

RAF, MEK1, MEK2

Autres noms:
  • Tafinlanr+Mekinist
Expérimental: Pemigatinib

For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.

FGFR2

Autres noms:
  • Pémazyre

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Disease control rate
Délai: 16 weeks

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

16 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Duration of treatment
Délai: 5 years

Time on drug

5 years
Adverse Events
Délai: 5 years

Treatment-related grade ≥3 and serious adverse events

5 years
Overall response
Délai: 5 years

Best overall response (defined as patients by CR, PR, SD)

5 years
PFS
Délai: 5 years

Progression free survival

5 years
OS
Délai: 5 years

Overall survival

5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 décembre 2021

Achèvement primaire (Estimé)

25 novembre 2031

Achèvement de l'étude (Estimé)

25 novembre 2032

Dates d'inscription aux études

Première soumission

3 décembre 2021

Première soumission répondant aux critères de contrôle qualité

3 décembre 2021

Première publication (Réel)

16 décembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Investigators plan to share the clinical study report.

Délai de partage IPD

2026-2027

Critères d'accès au partage IPD

Will be made available through European regulatory CTIS programme.

Type d'informations de prise en charge du partage d'IPD

  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner